Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label study assessing feasibility and tolerability of sintilimab plus anlotinib as the second-line treatment for patients with advanced BTC

Next Previous
Trial Profile

An open label study assessing feasibility and tolerability of sintilimab plus anlotinib as the second-line treatment for patients with advanced BTC

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 28 Feb 2023 New trial record
  • 13 Feb 2023 Primary endpoint (Overall survival (OS)) has been met according to results published in the International Journal of Cancer
  • 13 Feb 2023 Results published in the International Journal of Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top